Drug Information

Drug (ID: DG01550) and It's Reported Resistant Information
Name
Poziotinib
Synonyms
Poziotinib; 1092364-38-9; UNII-OEI6OOU6IK; HM781-36B; NOV120101; NOV-120101; 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one; OEI6OOU6IK; 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; HM-781-36B; 1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one; MFCD28044290; HM 781-36B; HM-781-36; 2-Propen-1-one, 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-; 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one; Poziotinib [INN]; 1-[4-({4-[(3,4-DICHLORO-2-FLUOROPHENYL)AMINO]-7-METHOXYQUINAZOLIN-6-YL}OXY)PIPERIDIN-1-YL]PROP-2-EN-1-ONE; HM-78136B; Poziotinib [USAN]; C23H21Cl2FN4O3; Poziotinib (HM781-36B); GTPL7903; SCHEMBL3391764; CHEMBL3545154; DTXSID80148853; EX-A528; HMS3673K03; AMY24248; BCP08270; NOV-1201; WHO 9736; BDBM50468247; NSC783296; NSC800856; s7358; ZINC95930125; AKOS026674078; CCG-264748; CS-3942; DB12114; NOV 120101; NSC-783296; NSC-800856; SB16882; NCGC00386427-01; NCGC00386427-02; AC-29021; AS-74851; BP161454; DA-47945; HY-15730; SY235762; HM 781-36; B5827; FT-0752903; A13044; J-690026; Q27088426; 1-[4-[4-(3,4-Dichloro-2-fluorophenylamino)-7-methoxyquinazoline-6-yloxy]-1-piperidinyl]-2-propene-1-one
    Click to Show/Hide
Indication
In total 6 Indication(s)
Atopic dermatitis [ICD-11: EA80]
Phase 2
[1]
Essential thrombocythemia [ICD-11: 3B63]
Phase 2
[1]
Essential thrombocythemia [ICD-11: 3B63]
Phase 2
[1]
High-risk myelofibrosis [ICD-11: 2A20]
Phase 2
[1]
Pancreatic cancer [ICD-11: 2C10]
Phase 2
[1]
Vitiligo [ICD-11: ED63]
Phase 2
[1]
Structure
Target Janus kinase 1 (JAK-1) JAK1_HUMAN [2]
Janus kinase 2 (JAK-2) JAK2_HUMAN [2]
Urokinase plasminogen activator surface receptor (PLAUR) UPAR_HUMAN [2]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
6
IsoSMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
InChI
InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
InChIKey
LPFWVDIFUFFKJU-UHFFFAOYSA-N
PubChem CID
25127713
TTD Drug ID
D04LKS
DrugBank ID
DB12114
Type(s) of Resistant Mechanism of This Drug
  ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration IF-insertion
p.A763_Y764insFQEA (c.2290_2291insTTCAAGAGGCAT)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The if-insertion p.A763_Y764insFQEA (c.2290_2291insTTCAAGAGGCAT) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.A767_V769 (c.2299_2307)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.A767_V769 (c.2299_2307) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.S768_D770 (c.2302_2310)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.S768_D770 (c.2302_2310) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.N771_H773 (c.2311_2319)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.N771_H773 (c.2311_2319) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration IF-insertion
p.P772_H773insGNP (c.2316_2317insGGTAACCCT)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The if-insertion p.P772_H773insGNP (c.2316_2317insGGTAACCCT) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [2]
Molecule Alteration Duplication
p.Y772_A775 (c.2314_2325)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.Y772_A775 (c.2314_2325) in gene ERBB2 cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [2]
Molecule Alteration Complex-indel
p.G776_776delinsVV (c.2326_2328delinsGTAGTA)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The complex-indel p.G776_776delinsVV (c.2326_2328delinsGTAGTA) in gene ERBB2 cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [2]
Molecule Alteration Complex-indel
p.G776_776delinsVC (c.2326_2328delinsGTATGT)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The complex-indel p.G776_776delinsVC (c.2326_2328delinsGTATGT) in gene ERBB2 cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [2]
Molecule Alteration Duplication
p.G778_P780 (c.2332_2340)
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.G778_P780 (c.2332_2340) in gene ERBB2 cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [1]
Molecule Alteration Duplication
p.G778_P780 (c.2332_2340)/p.780_Y781insGSP
 Molecule Info 
Sensitive Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z]
 Disease Info 
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
Experiment for
Molecule Alteration		 Sanger cDNA sequencing assay
Experiment for
Drug Resistance		 CCK-8 assay
Lung cancer [ICD-11: 2C25]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.A767_V769 (c.2299_2307)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.A767_V769 (c.2299_2307) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Complex-indel
p.N771_771delinsFH (c.2311_2313delinsTTTCAT)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The complex-indel p.N771_771delinsFH (c.2311_2313delinsTTTCAT) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration IF-insertion
p.P772_H773insGNP (c.2316_2317insGGTAACCCT)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The if-insertion p.P772_H773insGNP (c.2316_2317insGGTAACCCT) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.A767_V769 (c.2299_2307)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.A767_V769 (c.2299_2307) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.S768_D770 (c.2302_2310)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.S768_D770 (c.2302_2310) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Complex-indel
p.D770_770delinsGY (c.2308_2310delinsGGTTAT)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The complex-indel p.D770_770delinsGY (c.2308_2310delinsGGTTAT) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.D770_P772 (c.2308_2316)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.D770_P772 (c.2308_2316) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration IF-insertion
p.D770_N771insG (c.2310_2311insGGT)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The if-insertion p.D770_N771insG (c.2310_2311insGGT) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Duplication
p.N771_H773 (c.2311_2319)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.N771_H773 (c.2311_2319) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [2]
Molecule Alteration Duplication
p.Y772_A775 (c.2314_2325)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The duplication p.Y772_A775 (c.2314_2325) in gene ERBB2 cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target.
Key Molecule: Epidermal growth factor receptor (EGFR) [2]
Molecule Alteration Missense mutation
p.S768I (c.2303G>T)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
CUTO14 cells N.A. . N.A.
In Vivo Model Female nu/nu nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Cell Titer Glo assay
Mechanism Description The missense mutation p.S768I (c.2303G>T) in gene EGFR cause the sensitivity of Poziotinib by aberration of the drug's therapeutic target
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [1]
Molecule Alteration Duplication
p.Y772_A775 (c.2314_2325)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
Experiment for
Molecule Alteration		 Sanger cDNA sequencing assay
Experiment for
Drug Resistance		 CCK-8 assay
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [3]
Molecule Alteration Duplication
p.Y772_A775 (c.2314_2325)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [3]
Molecule Alteration Complex-indel
p.G776_776delinsVC (c.2326_2328delinsGTATGT)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [3]
Molecule Alteration Missense mutation
p.E812K (c.2434G>A)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [1]
Molecule Alteration Complex-indel
p.G776_776delinsVC (c.2326_2328delinsGTATGT)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Ba/F3 cells Colon Homo sapiens (Human) CVCL_0161
Experiment for
Molecule Alteration		 Sanger cDNA sequencing assay
Experiment for
Drug Resistance		 CCK-8 assay
References
Ref 1 Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro studyLung Cancer. 2018 Dec;126:72-79. doi: 10.1016/j.lungcan.2018.10.019. Epub 2018 Oct 17.
Ref 2 Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerNat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23.
Ref 3 Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung AdenocarcinomaClin Lung Cancer. 2018 Sep;19(5):e775-e781. doi: 10.1016/j.cllc.2018.05.018. Epub 2018 Jun 5.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.